Current Report Filing (8-k)
May 17 2016 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
|
May 17, 2016
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35076
|
31-1080091
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
5600 Blazer Parkway, Suite 200, Dublin, Ohio
|
43017
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(614) 793-7500
|
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On May 17, 2016, Navidea Biopharmaceuticals,
Inc. (the “Company”) issued a press release regarding its consolidated financial results for the quarter ended March
31, 2016. A copy of the Company’s May 17, 2016 press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
The information contained in Item 2.02 of
this Current Report on Form 8-K, including exhibit 99.1 attached hereto, shall not be treated as “filed” for purposes
of the Securities Exchange Act of 1934, as amended.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit
|
|
Number
|
Exhibit Description
|
|
|
99.1
|
Press Release dated May 17, 2016.
|
Statements contained or incorporated
by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future financial performance, new and existing products and
technologies, and markets for the Company’s products, are forward-looking statements. The words “believe,”
“expect,” “anticipate,” “estimate,” “project,” and similar expressions
identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements
involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results
due to many factors including, but not limited to, the Company’s continuing operating losses, ability to repay debt,
the outcome of the CRG litigation, uncertainty of market acceptance, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent
Annual Report on Form 10-K and other filings with the United States Securities and Exchange Commission. The Company
undertakes no obligation to publicly update or revise any forward-looking statements.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Navidea Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
Date:
May 17, 2016
|
By:
|
/s/ Jed A. Latkin
|
|
|
Jed A. Latkin, Interim Chief Operating Officer
|
|
|
|
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024